Terms ending in 2031
Every in-force patent on Amgen Inc.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,790,313 | Syringe Adapter In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,883,151 | IL-17 Receptor Antibody Formulation In force · High confidence | Amgen K-A, Inc. | In force | High confidence | |
| US 10,808,033 | IL-17 Receptor Antibody Formulation In force · High confidence | Amgen K-A, Inc. | In force | High confidence | |
| US 11,505,612 | Method of Treating Diseases Using an IL-17 Receptor Antibody Formulation In force · High confidence | Amgen K-A, Inc. | In force | High confidence | |
| US 8,735,384 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,222,251 | Pyridopyridazine Compounds, Compositions and Methods of Use In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 9,302,056 | Vaccination syringe In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 10,213,562 | Vaccination syringe In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,415,485 | Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,163,909 | Substituted Hydroxyethyl Amine Compounds as Beta-Secretase Modulators and Methods of Use In force · High confidence | Amgen Inc. | In force | High confidence | |
| 47 more term ends in 2031 · Pro | |||||
10 of 57 patents shown. Soonest term end first, then patent number.
Pro members see all 57.
51 of these are in force and held by Amgen Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.